ArticleSAGE open medical case reports2025
Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting TYK2 in Cutaneous Autoimmunity: Deucravacitinib-Induced Remission of Discoid Lupus and Psoriasis with Supportive Confocal Microscopy Findings.Dermatology and therapy · 2026Article
- Deucravacitinib in dermatology: current indication and existing off-label data.Drugs in context · 2026Review
- Treatment of concomitant alopecia areata and systemic lupus erythematosus with ivarmacitinib: a case report and literature review.Frontiers in medicine · 2026Article
- Review of Promising Off-Label Use of Deucravacitinib.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment option in systemic lupus erythematosus with potential applicability to discoid lupus erythematosus. We describe a 48-year-old woman with multiple treatment-refractory scalp plaques and associated alopecia treated with deucravacitinib. She demonstrated resolution of symptoms and 1-2 cm hair regrowth at a 3-month follow-up, with significant hair regrowth and reduction in plaque size at a 6-month follow-up. The patient tolerated the medication well with no side effects. This case highlights the potential of deucravacitinib as an effective therapy for refractory discoid lupus erythematosus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.